ArticleNeuroImage. Clinical2015
T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease.
Article in NeuroImage. Clinical, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 33 citations in OpenAlex.
- Grading of glioma and prediction of IDH mutation status via longitudinal relaxation time in rotating frame mapping on 5-T magnetic resonance imaging: added value to amide proton transfer-weighted imaging.Quantitative imaging in medicine and surgery · 2026Article
- Quantitative magnetic resonance imaging in Alzheimer's disease: a narrative review.Quantitative imaging in medicine and surgery · 2025Review
- Optimized MR pulse sequence for high-resolution brain 3D-T1ρ mapping with weighted spin-lock acquisitions.Magnetic resonance in medicine · 2025Article
- Can T1-Weighted Magnetic Resonance Imaging Significantly Improve Mini-Mental State Examination-Based Distinguishing Between Mild Cognitive Impairment and Early-Stage Alzheimer's Disease?Journal of Alzheimer's disease : JAD · 2023Article
- Hippocampal acidity and volume are differentially associated with spatial navigation in older adults.NeuroImage · 2021Article
- Three-dimensional whole-brain simultaneous T1, T2, and T1ρ quantification using MR Multitasking: Method and initial clinical experience in tissue characterization of multiple sclerosis.Magnetic resonance in medicine · 2021Article
- Cardiac magnetic resonance fingerprinting: Trends in technical development and potential clinical applications.Progress in nuclear magnetic resonance spectroscopy · 2021Review
- Three-Dimensional GRE TMagnetic resonance in medicine · 2020Article
- Subcortical T1-Rho MRI Abnormalities in Juvenile-Onset Huntington's Disease.Brain sciences · 2020Article
- Proton Exchange Magnetic Resonance Imaging: Current and Future Applications in Psychiatric Research.Frontiers in psychiatry · 2020Review
- Comparison of TThe Journal of neuropsychiatry and clinical neurosciences · 2020Article
- Taming Alzheimer's disease: New perspectives, newer horizons.Iranian journal of neurology · 2017Review
- Differentiation of brain tumor-related edema based on 3D T1rho imaging.European journal of radiology · 2017Article
- MRI of rod cell compartment-specific function in disease and treatment in vivo.Progress in retinal and eye research · 2016Review
- Magnetic Resonance Imaging to Detect Early Molecular and Cellular Changes in Alzheimer's Disease.Frontiers in aging neuroscience · 2016Review
- Comparative analysis of PET and multiparametric MRI biomarkers in Alzheimer's disease continuum cohort.Journal of Alzheimer's disease reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 3 countries.
Funding
Abstract
In the current study, we have evaluated the performance of magnetic resonance (MR) T1rho (T1ρ) imaging and CSF biomarkers (T-tau, P-tau and Aβ-42) in characterization of Alzheimer's disease (AD) patients from mild cognitive impairment (MCI) and control subjects. With informed consent, AD (n = 27), MCI (n = 17) and control (n = 17) subjects underwent a standardized clinical assessment and brain MRI on a 1.5-T clinical-scanner. T1ρ images were obtained at four different spin-lock pulse duration (10, 20, 30 and 40 ms). T1ρ maps were generated by pixel-wise fitting of signal intensity as a function of the spin-lock pulse duration. T1ρ values from gray matter (GM) and white matter (WM) of medial temporal lobe were calculated. The binary logistic regression using T1ρ and CSF biomarkers as variables was performed to classify each group. T1ρ was able to predict 77.3% controls and 40.0% MCI while CSF biomarkers predicted 81.8% controls and 46.7% MCI. T1ρ and CSF biomarkers in combination predicted 86.4% controls and 66.7% MCI. When comparing controls with AD, T1ρ predicted 68.2% controls and 73.9% AD, while CSF biomarkers predicted 77.3% controls and 78.3% for AD. Combination of T1ρ and CSF biomarkers improved the prediction rate to 81.8% for controls and 82.6% for AD. Similarly, on comparing MCI with AD, T1ρ predicted 35.3% MCI and 81.9% AD, whereas CSF biomarkers predicted 53.3% MCI and 83.0% AD. Collectively CSF biomarkers and T1ρ were able to predict 59.3% MCI and 84.6% AD. On receiver operating characteristic analysis T1ρ showed higher sensitivity while CSF biomarkers showed greater specificity in delineating MCI and AD from controls. No significant correlation between T1ρ and CSF biomarkers, between T1ρ and age, and between CSF biomarkers and age was observed. The combined use of T1ρ and CSF biomarkers have promise to improve the early and specific diagnosis of AD. Furthermore, disease progression form MCI to AD might be easily tracked using these two parameters in combination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.